학술논문
LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy
Document Type
Abstract
Author
Source
In Annals of Oncology October 2023 34 Supplement 2:S1286-S1286
Subject
Language
ISSN
0923-7534